• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).

PURPOSE: The Age-Related Eye Disease Study (AREDS) demonstrated beneficial effects of oral supplementation with antioxidant vitamins and minerals on the development of advanced age-related macular degeneration (AMD) in persons with at least intermediate AMD (bilateral large drusen with or without pigment changes). Observational data suggest that other oral nutrient supplements might further reduce the risk of progression to advanced AMD. The primary purpose of the Age-Related Eye Disease Study 2 (AREDS2) is to evaluate the efficacy and safety of lutein plus zeaxanthin (L+Z) and/or ω-3 long-chain polyunsaturated fatty acid (LCPUFA) supplementation in reducing the risk of developing advanced AMD. The study also assesses the reduction in zinc and the omission of β-carotene from original AREDS formulation. DESIGN: Multicenter, phase III, randomized, controlled clinical trial. PARTICIPANTS: Persons aged 50 to 85 with bilateral intermediate AMD or advanced AMD in 1 eye. METHODS: All participants were randomly assigned to placebo (n = 1012), L+Z (10 mg/2 mg; n = 1044), ω-3 LCPUFAs (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069), or the combination of L+Z and ω-3 LCPUFAs (n = 1078). All participants were offered a secondary randomization to 1 of 4 variations of the original AREDS formulation keeping vitamins C (500 mg) and E (400 IU) and copper (2 mg) unchanged while varying zinc and β-carotene as follows: Zinc remains at the original level (80 mg), lower only zinc to 25 mg, omit β-carotene only, or lower zinc to 25 mg and omit β-carotene. MAIN OUTCOME MEASURES: Progression to advanced AMD determined by centralized grading of annual fundus photographs. RESULTS: We enrolled 4203 participants at 82 clinical centers located in the United States. Population characteristics at baseline were as follows: Mean age, 74 years; 57% female; 97% white; 7% current smokers; 19% with prior cardiovascular disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively. Ocular characteristics include 59% with bilateral large drusen, 32% with advanced AMD in 1 eye and mean visual acuity of 20/32 in eyes without advanced AMD. CONCLUSIONS: This report presents the AREDS2 study design and the participants' baseline demographic and ocular characteristics.

Pubmed ID: 22840421

Authors

  • AREDS2 Research Group
  • Chew EY
  • Clemons T
  • SanGiovanni JP
  • Danis R
  • Domalpally A
  • McBee W
  • Sperduto R
  • Ferris FL

Journal

Ophthalmology

Publication Data

November 5, 2012

Associated Grants

  • Agency: NEI NIH HHS, Id: N01-EY-5-0007
  • Agency: NEI NIH HHS, Id: ZIA EY000485-01

Mesh Terms

  • Aged
  • Aged, 80 and over
  • Dietary Supplements
  • Disease Progression
  • Docosahexaenoic Acids
  • Drug Therapy, Combination
  • Eicosapentaenoic Acid
  • Epidemiologic Methods
  • Fatty Acids, Omega-3
  • Female
  • Humans
  • Lutein
  • Macular Degeneration
  • Male
  • Middle Aged
  • Research Design
  • Treatment Outcome
  • Visual Acuity
  • Xanthophylls
  • Zeaxanthins